SCHEMBL29939637

SCHEMBL29939637

CCOC(=O)c1c(-c2cccc(F)c2F)nn2cccnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 3/20 0.41
IDO1 P14902 1/20 0.40
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
PDE2A O00408 1/20 0.39
TDP2 O95551 2/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CCNE2 O96020 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KMT2A Q03164 1/20 0.38
ALOX5 P09917 2/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29939563 0.91 JAK2 (0.47) TGFBR1IDO1JAK2JAK3PDE2A
SCHEMBL30988101 0.90 ELANE (0.40) TGFBR1IDO1PDE2ATDP2KMT2A
SCHEMBL30029014 0.89 PDE2A (0.41) TGFBR1IDO1JAK2JAK3PDE2A
SCHEMBL23013599 0.88 PDE2A (0.41) TGFBR1IDO1PDE2ATDP2NPC1
SCHEMBL29939370 0.84 SLC34A1 (0.45) TGFBR1IDO1JAK2JAK3PDE2A
SCHEMBL29939402 0.84 TGFBR1 (0.41) TGFBR1IDO1JAK2JAK3PDE2A
SCHEMBL27230012 0.83 ALOX5 (0.41) TGFBR1IDO1PDE2ANPC1RAB9A
SCHEMBL29703840 0.83 CCNE2 (0.43) TGFBR1IDO1CCNE2CCNE1CDK2
SCHEMBL23013296 0.83 CCNE2 (0.43) TGFBR1IDO1CCNE2CCNE1CDK2
SCHEMBL29939653 0.82 MAPT (0.40) TGFBR1JAK2JAK3PDE2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 US disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 US disclosed
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-10-13 US disclosed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12227507-B2 Pharmaceutical compounds CHRNA6, GABRA6, CHRNA7 TGFBR1 858/4885IDO1 2520/4885JAK2 1583/4885
US-11634425-B2 Pharmaceutical compounds GABRA6, CHRNA6, CNR1 TGFBR1 954/4885IDO1 2344/4885JAK2 1712/4885
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS CHRNA6, GABRA6, CHRNA7 TGFBR1 858/4885IDO1 2520/4885JAK2 1583/4885
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS GABRA6, CNR1, CHRNA6 TGFBR1 1045/4885IDO1 2062/4885JAK2 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.